Angiotensin II Type 1 Receptor Tachyphylaxis Is Defined by Agonist Residence Time. 2022

Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
Department of Biochemistry and Immunology, Ribeirao Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil (D.A.D., L.T.P.-e.-S., E.B.O., C.M.C.-N.).

Several GPCRs (G-protein-coupled receptors) have been reported to exhibit tachyphylaxis, which is an acute loss of functional receptor response after repeated stimuli with an agonist. GPCRs are important clinical targets for a wide range of disorders. Therefore, elucidation of the ligand features that contribute to receptor tachyphylaxis and signaling events underlying this phenomenon is important for drug discovery and development. In this study, we examined the role of ligand-binding kinetics in the tachyphylaxis of AT1R (angiotensin II type 1 receptor) using bioluminescence resonance energy transfer assays to monitor signaling events under both kinetic and equilibrium conditions. We investigated AT1R signal transduction and translocation promoted by the endogenous tachyphylactic agonist Ang II (angiotensin II) and its analogs, described previously for inducing reduced receptor tachyphylaxis. Estimation of binding kinetic parameters of the ligands revealed that the residence time of Ang II was higher than that of the analogs, resulting in more sustained Gq protein activation and recruitment of β-arrestin than that promoted by the analogs. Furthermore, we observed that Ang II led to more sustained internalization of the receptor, thereby retarding its recycling to the plasma membrane and preventing further receptor responses. These results show that the apparent lack of tachyphylaxis in the studied analogs resulted from their short residence time at the AT1R. In addition, our data highlight the relevance of complete characterization of novel GPCR drug candidates, taking into account their receptor binding kinetics as well.

UI MeSH Term Description Entries
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D013618 Tachyphylaxis Rapidly decreasing response to a drug or physiologically active agent after administration of a few doses. In immunology, it is the rapid immunization against the effect of toxic doses of an extract or serum by previous injection of small doses. (Dorland, 28th ed)
D015398 Signal Transduction The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway. Cell Signaling,Receptor-Mediated Signal Transduction,Signal Pathways,Receptor Mediated Signal Transduction,Signal Transduction Pathways,Signal Transduction Systems,Pathway, Signal,Pathway, Signal Transduction,Pathways, Signal,Pathways, Signal Transduction,Receptor-Mediated Signal Transductions,Signal Pathway,Signal Transduction Pathway,Signal Transduction System,Signal Transduction, Receptor-Mediated,Signal Transductions,Signal Transductions, Receptor-Mediated,System, Signal Transduction,Systems, Signal Transduction,Transduction, Signal,Transductions, Signal
D044140 Receptor, Angiotensin, Type 1 An angiotensin receptor subtype that is expressed at high levels in a variety of adult tissues including the CARDIOVASCULAR SYSTEM, the KIDNEY, the ENDOCRINE SYSTEM and the NERVOUS SYSTEM. Activation of the type 1 angiotensin receptor causes VASOCONSTRICTION and sodium retention. Angiotensin II Type 1 Receptor,Angiotensin Type 1 Receptor,Angiotensin Type 1a Receptor,Angiotensin Type 1b Receptor,Receptor, Angiotensin, Type 1a,Receptor, Angiotensin, Type 1b,Angiotensin AT1 Receptor,Angiotensin AT1a Receptor,Angiotensin AT1b Receptor,Angiotensin II Type 1a Receptor,Angiotensin II Type 1b Receptor,Receptor, Angiotensin II Type 1,Receptor, Angiotensin II Type 1a,Receptor, Angiotensin II Type 1b,AT1 Receptor, Angiotensin,AT1a Receptor, Angiotensin,AT1b Receptor, Angiotensin,Receptor, Angiotensin AT1,Receptor, Angiotensin AT1a,Receptor, Angiotensin AT1b
D047228 Angiotensin II Type 1 Receptor Blockers Agents that antagonize ANGIOTENSIN II TYPE 1 RECEPTOR. Included are ANGIOTENSIN II analogs such as SARALASIN and biphenylimidazoles such as LOSARTAN. Some are used as ANTIHYPERTENSIVE AGENTS. Angiotensin II Type 1 Receptor Antagonist,Angiotensin II Type 1 Receptor Blocker,Sartan,Angiotensin 2 Type 1 Receptor Antagonists,Angiotensin II Type 1 Receptor Antagonists,Sartans,Selective Angiotensin II Receptor Antagonists,Type 1 Angiotensin Receptor Antagonists,Type 1 Angiotensin Receptor Blockers
D057809 HEK293 Cells A cell line generated from human embryonic kidney cells that were transformed with human adenovirus type 5. 293T Cells,HEK 293 Cell Line,HEK 293 Cells,Human Embryonic Kidney Cell Line 293,Human Kidney Cell Line 293,293 Cell, HEK,293 Cells, HEK,293T Cell,Cell, 293T,Cell, HEK 293,Cell, HEK293,Cells, 293T,Cells, HEK 293,Cells, HEK293,HEK 293 Cell,HEK293 Cell
D019808 Losartan An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II. 2-Butyl-4-chloro-1-((2'-(1H-etrazol-5-yl) (1,1'-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol,Cozaar,DuP-753,Losartan Monopotassium Salt,Losartan Potassium,MK-954,MK954,DuP 753,DuP753,MK 954,Monopotassium Salt, Losartan,Potassium, Losartan,Salt, Losartan Monopotassium

Related Publications

Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
October 1994, Hypertension (Dallas, Tex. : 1979),
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
July 2006, The Journal of biological chemistry,
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
December 1994, Journal of hypertension,
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
June 2024, British journal of anaesthesia,
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
January 2000, Nihon rinsho. Japanese journal of clinical medicine,
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
July 2006, Nihon rinsho. Japanese journal of clinical medicine,
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
February 2001, Circulation,
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
June 2009, Hypertension (Dallas, Tex. : 1979),
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
April 2001, FEBS letters,
Diego A Duarte, and Lucas T Parreiras-E-Silva, and Eduardo B Oliveira, and Michel Bouvier, and Claudio M Costa-Neto
July 2006, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!